查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848738

按成像技术、应用、最终用户、切片检查类型和引导系统分類的切片检查引导系统市场—2025-2032年全球预测

Biopsy Guidance System Market by Imaging Technology, Application, End User, Biopsy Type, Guidance System - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，切片检查引导系统市场规模将达到 27.8 亿美元，复合年增长率为 7.61%。

关键市场统计数据
基准年 2024 15.4亿美元
预计年份：2025年 16.6亿美元
预测年份 2032 27.8亿美元
复合年增长率 (%) 7.61%

为切片检查引导领域提供明确的指导，重点阐述了临床驱动因素、技术推动因素、监管压力以及相关人员的业务需求。

切片检查引导生态系已进入创新期，这得益于临床需求与技术成熟度的整合。临床医师要求在最大限度减少患者不适和手术风险的同时，提高诊断准确性，从而提升了先进影像技术和引导平台的重要性。同时，设备製造商和解决方案提供者正致力于整合、互通性和工作流程效率的提升，以缩短手术时间并提高可重复性。这些因素正在重塑医院、门诊中心和诊断机构的采购标准。

在此背景下，相关人员必须应对临床应用路径、监管预期和报销机制之间错综复杂的相互作用。提供能够证明其相对临床价值的证据日益影响应用决策，支付方也更加关注手术结果和成本动态。因此，产品开发蓝图优先考虑易用性、降低手术操作差异以及与现有影像基础设施的兼容性。本引言透过揭示定义当前市场发展阶段的临床驱动因素、技术推动因素和营运重点，为后续分析奠定了更广泛的基础。

机器人技术、多模态成像和软体智慧领域的创新如何重新定义切片检查引导的手术精度和临床价值

切片检查引导领域正经历一场变革，机器人技术、影像技术的进步以及软体智慧的融合，显着提升了手术的精准度和临床可靠性。机器人辅助技术正从概念验证阶段走向成熟，逐渐融入常规工作流程，即使在解剖结构复杂的病例中，也能实现高度可重复的穿刺路径和精准的靶向定位。同时，电脑断层扫描（CT）和磁振造影）等影像技术不断提升软组织对比度和空间分辨率，超音波平台也正朝着更先进的二维、三维和多普勒成像方向发展，进一步拓展了照护现场应用的潜力。

此外，即时导航系统和影像融合技术的兴起，也为结合各种显像模式优势的多模态方法铺路。软体主导的决策支持，包括病灶特征分析和轨迹规划，正逐渐成为综合解决方案的必备组成部分。综合这些变化，价值提案正在重新调整。买家越来越青睐那些能够减少重复手术、缩短学习曲线并与电子健康记录整合的系统。随着应用普及速度的加快，那些优先考虑检验的临床结果和互通生态系统的供应商，将更有利于在各种临床环境中获得持续认可。

评估近期美国关税调整对导引系统采购、供应链韧性和产品架构的营运和策略影响。

美国近期关税政策的变化为切片检查引导系统的跨境采购和供应链规划带来了复杂性。关税调整影响范围广泛，涵盖从影像处理电子元件到精密机械组装等众多零件，导致到岸成本变化，促使跨国供应商重新评估筹资策略。为此，许多供应商正在探索近岸外包方案，实现供应商多元化，并调整库存策略以应对成本的突发波动。这些营运措施旨在保护净利率，同时确保优先临床客户的产品供应。

关税主导的转变不仅会影响直接成本，还会影响产品架构和售后服务经济效益。製造商可能会重新设计模组，以依赖国内采购的子组件，或改变组装以降低风险。此类重新设计也会影响监管文件和检验时间表，因此需要积极主动地进行变更管理。从买方的角度来看，采购负责人在更换供应商时必须考虑更长的交货时间和潜在的重新验证工作。总体而言，关税正在加速策略前置作业时间弹性规划的製定，并使商业敏捷性成为价值链上相关人员的核心竞争力。

将显像模式、临床应用、终端用户环境、切片检查技术和引导平台与可操作的商业化路径进行细分洞察

关键细分市场动态揭示了临床需求与技术差异化的交汇点，为有针对性的投资和商业化策略提供了指南。基于影像技术，可分为电脑断层扫描（CT）、磁振造影（MRI）、立体定位系统、超音波和X光设备，其中超音波可进一步细分为二维超音波、3D超音波和多普勒超音波。基于应用领域，可分为乳房、肾臟、肝臟、肺部、前列腺和甲状腺等临床重点领域，每种应用都对影像、穿刺和切片检查操作提出了独特的要求，这些要求会影响产品设计和培训需求。

终端使用者细分将门诊手术中心、影像诊断中心、医院和门诊诊所确定为主要治疗场所，其中医院进一步分为私人医院和公立医院。按切片检查类型划分，诊所区分粗针穿刺活检和细针穿刺活检，粗针切片技术又细分为弹簧式和真空辅助式，这些选择反映了组织产量、手术创伤性和病理处理流程之间的权衡。最后，导航粗针穿刺切片偏好分为手动系统和机器人系统，其采用轨迹取决于对准确性提升、工作流程中断程度和临床医生熟练程度的预期。综上所述，这些细分凸显了产品客製化、差异化临床证据产生以及客製化服务模式的机会，这些模式能够满足每种方式、应用、终端用户和手术的特定需求。

影响美洲、中东和非洲以及亚太地区招募、伙伴关係和商业化策略的区域动态和商业路径

区域动态影响技术的普及速度、报销框架和伙伴关係生态系统，理解这些细微差别对于有效的市场进入和规模扩大策略至关重要。在美洲，需求模式受到支付方格局的异质性和临床创新中心集中化的影响，这些因素推动了先进指导平台的早期应用。采购决策通常受临床证据和医院系统优先事项的影响，而门诊中心则越来越倾向于寻求高性价比、高通量的解决方案。在欧洲、中东和非洲，监管的多样性和基础设施成熟度的差异导致了不同的普及曲线，中心三级医院通常作为先进可携式的枢纽，而偏远和资源匮乏的地区则优先考虑经济高效、便携式治疗方法。

亚太地区医疗体系的快速现代化和庞大的患者数量，既为规模化发展创造了机会，也催生了在地化商业化策略的必要性。区域人才库、本地製造奖励以及经销伙伴，都会进一步影响企业如何部署培训、服务模式和售后支援。透过将产品价值提案与区域临床需求和采购实际情况相结合，相关人员可以优化其市场推广顺序和伙伴关係选择，从而最大限度地提高临床影响力和商业性转换率。

竞争格局为买家带来临床证据、可互通的生态系统、模组化产品策略和全面的生命週期支援。

切片检查引导领域的竞争动态主要围绕着那些能够成功将硬体可靠性、竞争优势软体和卓越服务融为一体，形成完整价值提案的公司。主要企业透过持续投资于临床证据、法规遵循和互通性来脱颖而出，从而促进与医院资讯系统和影像檔案库的整合。提供模组化设计的产品生态系统，例如支援从手动引导扩展到机器人引导以及升级成像模组，往往更能吸引那些优先考虑未来发展前景和整体拥有成本的买家。

此外，提供全面培训、远端支援和预测性维护能力的公司可以降低流程差异，并提高客户维繫。设备製造商、软体供应商和临床中心之间的策略伙伴关係能够促进使用者社群的形成，从而产生真实世界证据并加速最佳实践的推广。新参与企业面临临床检验和服务连续性的高期望，而现有企业则必须透过不断改善使用者体验和展示可衡量的结果来防止产品同质化。因此，竞争优势将越来越依赖临床可靠性、整合能力和完善的售后服务的结合。

领导者需采取切实可行的策略重点，以落实产品开发、证据收集、供应链韧性以及商业性差异化服务模式。

产业领导者应优先采取一系列行动，将市场情报转化为永续的商业性优势和临床应用。首先，产品开发应与特定治疗方式的性能要求和最终用户的工作流程实际情况相符，投资于能够减少操作差异并帮助临床医生快速熟悉产品的解决方案。其次，在包括乳腺癌、肝癌、肺癌、前列腺癌、肾癌和甲状腺癌在内的关键应用领域建立强大的临床证据项目，以检验相对疗效并为有利的采购决策提供支持。第三，透过供应商多元化、评估近岸外包方案以及维持策略性库存来增强供应链韧性，从而降低关税和物流风险。

同时，我们将透过建立可互通的软体平台来降低技术应用门槛，这些平台能够促进影像融合、轨迹规划以及与电子健康记录的无缝整合。我们将开发满足医院、门诊手术中心、影像诊断中心和门诊诊所个人化需求的商业模式，提供灵活的资金筹措和配套服务协议，以缓解资金压力。最后，我们将投资于培训、远端支援和预测性维护，以减少停机时间并增强临床医生的信心。持续推动这些措施将改善临床疗效，加速技术应用，并加强与医疗系统和诊断服务提供者的长期伙伴关係。

一种透明的、以临床医生为中心的调查方法，结合了主要相关人员的参与、监管检验和情景分析，以支持可操作的见解。

本研究结合了对临床医生、采购专业人员和行业高管的访谈，并广泛查阅了监管指南、临床文献和产品规格，以确保获得以临床医生为中心的可靠见解。资料收集强调跨职能观点，以捕捉临床工作流程、培训需求和采购决策标准；分析方法结合了定性主题分析和产品功能及服务提供的结构化比较评估。这种方法有意优先考虑三角验证，以协调不同相关人员的观点，并揭示对商业化和临床应用具有实际意义的内容。

品质保证措施包括对照监管文件和同行评审的临床研究检验技术声明，以及与专家进行迭代审查以完善解读。在适用情况下，对供应链和营运场景进行敏感度测试，以评估不同关税和物流条件下的韧性。调查方法旨在做到透明和可重复，从而增强相关人员对研究结果的信心，并支持进行有针对性的后续分析，以解决特定的临床或商业问题。

整合临床、技术和商业性需求，为切片检查引导系统的应用和领先地位制定发展路径

总之，切片检查引导领域正从渐进式改善迈向一体化创新阶段，影像技术、机器人辅助技术和智慧软体的进步正在融合，重新定义手术标准。儘管临床上对更高精准度和更轻患者负担的需求推动了技术的普及，但采购选择越来越受到临床价值、互通性和服务连续性等因素的影响。关税和供应链动态进一步增加了策略复杂性，促使製造商和采购商优先考虑技术的韧性和灵活性。

对于相关人员，未来的发展方向在于将技术开发与具体应用需求相结合，投资于严格的临床检验，并提供能够反映不同终端使用者和区域实际情况的客製化商业和服务模式。能够成功将临床可靠性、营运可靠性和灵活部署模式相结合的主要企业，将引领技术应用，并创造可持续的竞争优势。产业正蓄势待发，即将迎来颠覆性变革，而及时做出的策略选择将决定谁能在技术从专业领域走向主流临床应用的过程中占据领导地位。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧驱动的自动病灶检测和即时回馈整合到切片检查引导系统中
  • 门诊临床环境中机器人切片检查导航平台的应用日益增多
  • 可携式照护现场超音波导引系统在微创切片检查中的应用
  • 将包括磁振造影、电脑断层扫描和超音波在内的多重模式影像融合技术整合到精准切片检查程序中
  • 利用电磁和光纤感测器开发针头追踪技术，以实现精准切片检查定位。
  • 扩大报销范围和监管核准将推动先进切片检查引导设备的应用。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章切片检查引导系统市场影像技术

  • 电脑断层扫描
  • 磁振造影
  • 立体定位放射治疗
  • 超音波
    • 二维超音波
    • 三维超音波
    • 多普勒超音波
  • X射线

第九章 按应用分類的切片检查引导系统市场

  • 胸部
  • 肾
  • 肝
  • 肺
  • 摄护腺
  • 甲状腺

第十章 依最终用户分類的切片检查引导系统市场

  • 门诊手术中心
  • 诊断影像中心
  • 医院
    • 私立医院
    • 公立医院
  • 门诊部

第十一章 依切片检查类型分類的切片检查引导系统市场

  • 核心针穿刺切片
    • 弹簧式
    • 真空辅助
  • 细针穿刺法

第十二章切片检查引导系统市场引导系统

  • 手动的
  • 机器人辅助

第十三章 各地区切片检查引导系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章切片检查引导系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国切片检查引导系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Hologic, Inc.
    • Canon Medical Systems Corporation
    • Medtronic plc
    • FUJIFILM Holdings Corporation
    • Hitachi, Ltd.
    • Samsung Medison Co., Ltd.
    • Esaote SpA
Product Code: MRR-C271879142B5

The Biopsy Guidance System Market is projected to grow by USD 2.78 billion at a CAGR of 7.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.54 billion
Estimated Year [2025] USD 1.66 billion
Forecast Year [2032] USD 2.78 billion
CAGR (%) 7.61%

A definitive orientation to the biopsy guidance landscape that frames clinical drivers, technology enablers, regulatory pressures, and operational imperatives for stakeholders

The biopsy guidance ecosystem has entered a period of accelerated innovation driven by converging clinical imperatives and technology maturation. Clinicians seek higher diagnostic accuracy while minimizing patient discomfort and procedural risk, which has elevated the importance of advanced imaging modalities and guidance platforms. Simultaneously, device manufacturers and solution providers are focusing on integration, interoperability, and workflow efficiencies that reduce procedure time and enhance reproducibility. These forces are reshaping procurement criteria across hospitals, ambulatory centers, and diagnostic facilities.

Against this backdrop, stakeholders must navigate a complex interplay of clinical adoption pathways, regulatory expectations, and reimbursement dynamics. Evidence generation that demonstrates comparative clinical value increasingly influences adoption decisions, and payers are scrutinizing procedure outcomes and cost-effectiveness. As a result, product development roadmaps prioritize ease of use, reduced procedural variability, and compatibility with existing imaging infrastructure. This introduction frames the broader context for subsequent analysis by highlighting the clinical drivers, technology enablers, and operational priorities that are defining the current phase of market evolution.

How converging innovations in robotics, multimodal imaging, and software intelligence are redefining procedural precision and clinical value in biopsy guidance

The landscape for biopsy guidance is experiencing transformative shifts as robotics, imaging refinement, and software intelligence converge to elevate procedural precision and clinical confidence. Robotic assistance is moving beyond proof of concept toward integration in routine workflows, enabling reproducible trajectories and enhanced targeting in anatomically challenging cases. Concurrently, imaging technologies such as computed tomography and magnetic resonance imaging are delivering finer soft tissue contrast and spatial resolution, while ultrasound platforms are diversifying into advanced two dimensional, three dimensional, and Doppler capabilities that expand point-of-care applicability.

Moreover, the rise of real-time navigation systems and image fusion is smoothing the path for multimodal approaches that combine the strengths of each imaging modality. Software-driven decision support, including lesion characterization and trajectory planning, is becoming an expected component of comprehensive solutions. Taken together, these shifts are recalibrating value propositions: purchasers increasingly reward systems that reduce repeat procedures, shorten learning curves, and integrate with electronic medical records. As adoption accelerates, suppliers who prioritize validated clinical outcomes and interoperable ecosystems will be best positioned to capture sustained preference across varied clinical settings.

Assessing the operational and strategic consequences of recent United States tariff shifts on procurement, supply chain resilience, and product architecture for guidance systems

Recent tariff developments in the United States have introduced increased complexity into cross-border procurement and supply chain planning for biopsy guidance systems. Tariff adjustments affect components ranging from imaging electronics to precision mechanical assemblies, altering landed costs and prompting multinational vendors to reassess sourcing strategies. In response, many suppliers are evaluating nearshoring options, diversifying supplier bases, and adjusting inventory policies to buffer against sudden cost fluctuations. These operational moves aim to preserve margin while maintaining product availability for high-priority clinical customers.

Beyond direct cost implications, tariff-driven shifts can influence product architecture and aftersales economics. Manufacturers may redesign modules to rely on domestically sourced subcomponents or alter assembly footprints to mitigate exposure. Such redesign efforts have downstream effects on regulatory documentation and validation timelines, necessitating proactive change management. From a buyer perspective, procurement officers need to account for longer lead times and potential requalification activities when switching suppliers. Overall, tariffs are accelerating strategic supply chain resilience planning and making commercial agility a core competency for stakeholders across the value chain.

Segmentation insights that map imaging modalities, clinical applications, end-user settings, biopsy techniques, and guidance platforms into actionable commercialization pathways

Key segmentation dynamics reveal where clinical demand and technological differentiation intersect, offering guidance for targeted investment and commercialization strategies. Based on imaging technology, the market spans computed tomography, magnetic resonance imaging, stereotactic systems, ultrasound, and X ray equipment, with ultrasound further differentiated into two dimensional ultrasound, three dimensional ultrasound, and Doppler ultrasound; each modality carries distinct strengths for tissue contrast, accessibility, and procedural context, shaping device integration priorities. Based on application, clinical focus areas encompass breast, kidney, liver, lung, prostate, and thyroid procedures, and each application imposes unique imaging, needle access, and biopsy handling requirements that influence product design and training needs.

End-user segmentation identifies ambulatory surgical centers, diagnostic imaging centers, hospitals, and outpatient clinics as primary care settings, with hospitals further split into private and public institutions; these distinctions matter because procurement cycles, capital availability, and clinical governance vary substantially across settings. Based on biopsy type, practices differentiate between core needle biopsy and fine needle aspiration, while core needle approaches subdivide into spring loaded and vacuum assisted mechanisms; the choice among these reflects tradeoffs between tissue yield, procedural invasiveness, and pathology processing workflows. Finally, guidance system preferences fall across manual and robotic assisted platforms, and adoption trajectories depend on perceived gains in accuracy, workflow disruption, and clinician proficiency. Collectively, these segmentation lenses highlight opportunities for product tailoring, differentiated clinical evidence generation, and customized service models that address the specific needs of each modality, application, end user, and procedural technique.

Regional dynamics and operational pathways across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, partnerships, and commercialization strategies

Regional dynamics shape adoption speed, reimbursement frameworks, and partnership ecosystems, and understanding these nuances is essential for effective market entry and scale strategies. In the Americas, demand patterns are influenced by heterogeneous payer landscapes and concentrated centers of clinical innovation that drive early adoption of advanced guidance platforms; procurement decisions are often shaped by clinical evidence and hospital system priorities, while ambulatory centers increasingly seek cost-effective, high-throughput solutions. In Europe, Middle East & Africa, regulatory diversity and variable infrastructure maturity lead to differentiated adoption curves where centralized tertiary hospitals frequently act as hubs for sophisticated technologies, while remote and resource-constrained settings prioritize cost-effective, portable modalities.

Across Asia-Pacific, a mix of rapidly modernizing healthcare systems and large patient volumes creates both scale opportunities and the need for localized commercialization strategies; demand often favors adaptable solutions that align with diverse clinical workflows and varying levels of imaging infrastructure. Regional talent pools, local manufacturing incentives, and distribution partnerships further influence how companies deploy training, service models, and aftermarket support. By aligning product value propositions with regional clinical imperatives and procurement realities, stakeholders can optimize market entry sequencing and partnership selection to maximize clinical impact and commercial uptake.

Competitive company dynamics that reward clinical evidence, interoperable ecosystems, modular product strategies, and comprehensive lifecycle support for buyers

Competitive dynamics within the biopsy guidance arena center on firms that successfully blend hardware reliability, software intelligence, and service excellence into a coherent value proposition. Leading companies differentiate through sustained investment in clinical evidence, regulatory stewardship, and interoperability that eases integration with hospital information systems and imaging archives. Product ecosystems that offer modularity-allowing facilities to scale from manual to robotic assisted guidance or to upgrade imaging modules-tend to resonate with purchasers who prioritize future-proofing and total cost of ownership.

Additionally, companies that provide comprehensive training, remote support, and predictive maintenance capabilities can reduce procedural variability and enhance customer retention. Strategic partnerships between device makers, software vendors, and clinical centers generate real-world evidence and foster user communities that accelerate best-practice dissemination. New entrants face high expectations around clinical validation and service continuity, while incumbents must guard against commoditization by continuously enhancing user experience and demonstrating measurable outcomes. Hence, competitive advantage increasingly derives from a combination of clinical credibility, integration capability, and aftersales service depth.

Actionable strategic priorities for leaders to align product development, evidence generation, supply chain resilience, and commercially differentiated service models

Industry leaders should pursue a prioritized set of actions that translate market intelligence into sustained commercial advantage and clinical adoption. First, align product development with modality-specific performance requirements and end-user workflow realities, investing in solutions that reduce procedural variability and support rapid clinician proficiency. Second, build robust clinical evidence programs across key applications such as breast, liver, lung, prostate, kidney, and thyroid to validate comparative benefits and support favorable procurement decisions. Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring options, and maintaining strategic inventories to mitigate tariff and logistics risks.

In parallel, cultivate interoperable software platforms that facilitate image fusion, trajectory planning, and seamless integration with electronic health records to lower adoption barriers. Develop tailored commercial models that address the distinct needs of hospitals, ambulatory surgical centers, diagnostic imaging centers, and outpatient clinics, and offer flexible financing or bundled service agreements to ease capital constraints. Finally, invest in training, remote support, and predictive maintenance to reduce downtime and enhance clinician confidence. Executed coherently, these actions will improve clinical outcomes, accelerate adoption, and strengthen long-term partnerships with health systems and diagnostic providers.

A transparent and clinician centered research methodology combining primary stakeholder engagement, regulatory validation, and scenario analysis to underpin practical insights

This research synthesizes primary interviews with clinicians, procurement professionals, and industry executives alongside an extensive review of regulatory guidance, clinical literature, and product specifications to ensure robust, clinician-centric insights. Data collection emphasized cross-functional perspectives to capture clinical workflows, training requirements, and procurement decision criteria, and analytic methods integrated qualitative thematic analysis with structured comparative assessments of product capabilities and service offerings. The approach intentionally prioritized triangulation to reconcile divergent stakeholder perspectives and to surface pragmatic implications for commercialization and clinical adoption.

Quality assurance measures included validation of technical claims against regulatory filings and peer-reviewed clinical studies, as well as iterative review cycles with domain experts to refine interpretations. Where applicable, sensitivity testing was applied to supply chain and operational scenarios to assess resilience under different tariff and logistics conditions. The methodology is designed to be transparent and reproducible, providing stakeholders with confidence in the findings and enabling targeted follow-up analyses to address specific clinical or commercial questions.

Synthesis of clinical, technological, and commercial imperatives that define the pathway to wider adoption and leadership in biopsy guidance systems

In conclusion, the biopsy guidance field is transitioning from incremental improvements toward a phase of integrative innovation where imaging evolution, robotic assistance, and smart software converge to redefine procedural standards. Clinical demand for higher accuracy and reduced patient burden is catalyzing adoption, while procurement choices are increasingly shaped by evidence of clinical value, interoperability, and service continuity. Tariff and supply chain dynamics add another layer of strategic complexity, prompting manufacturers and purchasers to prioritize resilience and agility.

For stakeholders, the path forward involves aligning technology development with specific application needs, investing in rigorous clinical validation, and delivering tailored commercial and service models that reflect the realities of diverse end users and regions. Companies that successfully marry clinical credibility with operational reliability and flexible deployment models will lead adoption and create durable competitive positions. The industry is poised for impactful advances, and timely strategic choices will determine who captures leadership as technologies move from specialized settings into mainstream clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven automated lesion detection and real-time feedback in biopsy guidance systems
  • 5.2. Rising adoption of robotic assisted biopsy navigation platforms in outpatient clinical settings
  • 5.3. Emergence of portable point of care ultrasound based guidance systems for minimally invasive biopsies
  • 5.4. Integration of multi modality imaging fusion including MRI CT and ultrasound in precision biopsy procedures
  • 5.5. Development of needle tracking technologies with electromagnetic and fiber optic sensors for accurate biopsy placement
  • 5.6. Expanding reimbursement coverage and regulatory approvals driving wider adoption of advanced biopsy guidance devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Guidance System Market, by Imaging Technology

  • 8.1. Computed Tomography
  • 8.2. Magnetic Resonance Imaging
  • 8.3. Stereotactic
  • 8.4. Ultrasound
    • 8.4.1. 2D Ultrasound
    • 8.4.2. 3D Ultrasound
    • 8.4.3. Doppler Ultrasound
  • 8.5. X Ray

9. Biopsy Guidance System Market, by Application

  • 9.1. Breast
  • 9.2. Kidney
  • 9.3. Liver
  • 9.4. Lung
  • 9.5. Prostate
  • 9.6. Thyroid

10. Biopsy Guidance System Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Imaging Centers
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Outpatient Clinics

11. Biopsy Guidance System Market, by Biopsy Type

  • 11.1. Core Needle Biopsy
    • 11.1.1. Spring Loaded
    • 11.1.2. Vacuum Assisted
  • 11.2. Fine Needle Aspiration

12. Biopsy Guidance System Market, by Guidance System

  • 12.1. Manual
  • 12.2. Robotic Assisted

13. Biopsy Guidance System Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopsy Guidance System Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopsy Guidance System Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GE HealthCare Technologies Inc.
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Koninklijke Philips N.V.
    • 16.3.4. Hologic, Inc.
    • 16.3.5. Canon Medical Systems Corporation
    • 16.3.6. Medtronic plc
    • 16.3.7. FUJIFILM Holdings Corporation
    • 16.3.8. Hitachi, Ltd.
    • 16.3.9. Samsung Medison Co., Ltd.
    • 16.3.10. Esaote S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPSY GUIDANCE SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY